Log In
BCIQ
Print this Print this
 

gerilimzumab (ARGX-109, RYI-008)

  Manage Alerts
Collapse Summary General Information
Company arGEN-X N.V.
DescriptionHuman mAb against interleukin-6 (IL-6)
Molecular Target Interleukin-6 (IL-6)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/20/2013

Undisclosed

Undisclosed

Undisclosed

10/08/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today